The Disease That Had Zero Treatments Just Got Its First
For 77 years, Alexander disease had zero approved treatments. Ionis Pharmaceuticals just changed that with Zanvastro, and the implications stretch far beyond one ultra-rare condition.
Imagine being diagnosed with a progressive brain disease and hearing your doctor say: "There's nothing we can give you." For people with Alexander disease, that was the reality for over seven decades. Every single one of those patients, from toddlers to adults, had exactly zero approved treatments.
Until September 3, 2026.
A First That Actually Deserves the Word "Historic"
The FDA approved Zanvastro (zilganersen), made by Ionis Pharmaceuticals, as the first and only disease-modifying treatment for Alexander disease. It covers both pediatric and adult patients. The agency also handed Ionis a Rare Pediatric Disease Priority Review Voucher, which is essentially a golden ticket the company can use (or sell) to fast-track a future drug review.
FDA neurology chief Emily Freilich called it a "landmark moment" for the Alexander disease community. That's not hyperbole for once.
Alexander disease attacks the brain's white matter, which you can think of as the insulation around your brain's wiring. When that insulation breaks down, signals misfire. Walking gets harder. Swallowing becomes dangerous. Seizures can follow. The disease is caused by mutations in a gene called GFAP, and it's relentlessly progressive.
It's also vanishingly rare. The best historical estimate puts it at roughly one case per 2.7 million people. Only about 500 cases have been reported worldwide since 1949. To put that in perspective, your odds of being struck by lightning in a given year are better than being diagnosed with Alexander disease.
The Trial That Made It Happen
Zanvastro is an antisense oligonucleotide, or ASO. Think of it like a molecular sticky note: it attaches to a specific piece of genetic messaging in your cells and tells it to shut up. In this case, the target is GFAP mRNA, reducing the faulty GFAP protein that drives Alexander disease.
The drug is delivered as a 50 mg injection into the spinal fluid every 12 weeks. That's quarterly dosing, which is manageable for a disease this severe.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The pivotal trial enrolled patients aged roughly two to sixty-five and used a 10-Meter Walk Test in those aged five and older to track gait speed over 61 weeks. The results told a clear story.
Patients on Zanvastro saw their gait speed decline by just 2.1%. The control group? They dropped 35.4%. That's a staggering difference. The statistical measure showed a 33.3% advantage for the drug (p=0.0412), meaning the result was unlikely to be a fluke.
Beyond walking, the data painted a broader picture of benefit. Patient-reported outcomes covering communication, swallowing, sleep, seizures, and day-to-day function all leaned in Zanvastro's favor. Younger children (ages two to four) also showed signs of improvement in gross motor function, though that was measured using a different scale called GMFM-88.
The safety profile looked solid. Most side effects were mild or moderate, with the most common being vomiting, back pain, cough, headache, and post-lumbar puncture syndrome (the headache you sometimes get after a spinal tap).
Why This Matters Beyond Alexander Disease
Zanvastro isn't just a win for one ultra-rare condition. It's a proof point for an entire therapeutic platform.
Ionis has been building its ASO technology for years, and the company now has a growing roster of approved neurological drugs. Spinraza (nusinersen) changed the game for spinal muscular atrophy. Qalsody (tofersen) became the first ASO approved for ALS tied to SOD1 mutations in 2023. Wainua (eplontersen) launched in early 2024 for a hereditary nerve disease caused by transthyretin buildup.
Zanvastro is the latest domino to fall, and it validates a playbook: find a genetically defined rare disease, design a molecular sticky note to silence the culprit gene, deliver it to the nervous system, and prove it works. Ionis is already running the same playbook in Angelman syndrome, another devastating neurological condition with a clear genetic target.
By 2024, 11 ASO drugs had earned FDA approval across various diseases. The pace is accelerating, and the pattern is clear: ultra-rare, genetically defined neurological diseases are becoming the sweet spot for this technology.
Wall Street's Verdict: Thumbs Up, With an Asterisk
H.C. Wainwright responded to the approval by reiterating a Buy rating on Ionis and bumping its price target to $115. Market coverage was broadly bullish, framing Zanvastro as a first-mover advantage in a space with zero competition.
But analysts were measured in their enthusiasm about the financial impact. With roughly 500 reported cases worldwide, Alexander disease is not going to be a blockbuster market. Several outlets described the revenue opportunity as "meaningful rather than transformational." Ionis hasn't disclosed U.S. pricing yet, saying only that the drug will be available "in the coming weeks."
The real financial story here isn't Zanvastro's sales. It's what the approval signals about Ionis's pipeline. Each successful neurological ASO launch builds regulatory muscle memory, manufacturing know-how, and commercial infrastructure. Think of it like a restaurant chain: the first location is expensive to open, but every one after that gets cheaper and faster.
Ionis is also setting up patient support through a program called Ionis Every Step, which will provide disease education, insurance navigation, affordability programs, and a dedicated Patient Education Manager. For a community this small, that kind of white-glove support matters enormously.
The Bigger Picture
For 77 years, Alexander disease had no answer. Families watched their children (or their parents, or their siblings) slowly lose the ability to walk, talk, and swallow, knowing that medicine had nothing to offer beyond managing symptoms.
That chapter is over. Zanvastro doesn't cure Alexander disease, but stabilizing gait speed while the control group loses more than a third of theirs is a dramatic result. It's the difference between walking to the kitchen and needing a wheelchair.
And for the broader world of rare neurological disease, this approval carries a simple, powerful message: if you can identify the gene, you might be able to silence it. One sticky note at a time.
6 min read
The Cancer Therapy That Killed Three People Who Didn't Have Cancer
Three patients with autoimmune diseases died in Novartis CAR-T trials, forcing the company to pause eight studies and the entire field to confront an uncomfortable question: can cancer's most powerful therapy ever be safe enough for diseases that aren't trying to kill you?
